Through the Integration of Eisai's Gastrointestinal Disease Business and Ajinomoto Pharmaceuticals Co., Ltd.
TOKYO, Mar 30, 2016 - (ACN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, Representative Corporate Officer and CEO: Haruo Naito, "Eisai") and Ajinomoto Co., Inc. (Headquarters: Tokyo, Representative Director, President and CEO: Takaaki Nishii, "Ajinomoto Co.") announced today that based on the integration agreement signed and announced on October 15, 2015, the gastrointestinal specialty pharma EA Pharma Co., Ltd. (EA Pharma) will be established through the splitting off of a portion of Eisai's gastrointestinal disease treatment business and its subsequent succession by Ajinomoto Co.'s wholly-owned subsidiary AJINOMOTO PHARMACEUTICALS CO., LTD. (Headquarters: Tokyo, Representative Director and President and CEO: Takashi Nagamachi, "AJINOMOTO PHARMACEUTICALS") via an absorption-type split as of April 1, 2016.
On April 1, 2016, Eisai's gastrointestinal disease business built up over more than 60 years and AJINOMOTO PHARMACEUTICALS, with amino acids at its core, will be integrated and commence business as EA Pharma, a gastrointestinal specialty pharma with a full value chain including research and development, production and logistics, sales and marketing. EA Pharma will strive toward realizing an Enterprise Architecture (EA) that will create new innovation from the combined knowledge of the two companies.
(Corporate Philosophy)The gastrointestinal system is the vital link between food as a source of energy, and life itself. As a Japanese specialty pharma in the field of gastrointestinal disease, EA Pharma aims to be a human health care (hhc) company that can get close to patients suffering from gastrointestinal diseases through specialized research and development as well as a unique product lineup, and provide a wide range ofsolutions to patients and their families.
(Corporate Vision)1. Specializing in gastrointestinal diseases such as inflammatory bowel disease (IBD), we will strive to address unmet medical needs through advanced research and development as well as focusing management resources on marketing activities from the patients' perspective.2. All employees will conduct business activities that adhere strictly to all laws and ethics, and as a company, EA Pharma will aim to maximize social value to contribute to increasing corporate value for both the Eisai and Ajinomoto groups.
Design rationale
Color: The logo continues to use the colors of the Eisai corporate logo. "The red and blue colors in the Eisai Logo mark represent red oxygenated blood flowing through the arteries and blue deoxygenated blood flowing through the veins. Both types of blood flow incessantly through the heart, and our task is to preventstagnation of the blood flow by promoting good health and improving quality of life."Shape: The image is the combination of the "E" from Eisai and "A" from Ajinomoto. Reflecting the desire to contribute to patients all over the world with EA Pharma products, the logo uses the earth as a design motif.
About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Source: Eisai
Contact:
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2016 JCN Newswire . All rights reserved.
